Humulin Nph (Insulin Human)

Humulin Nph is indicated for the long‑acting insulin needs of adults and children with diabetes, providing basal insulin coverage to maintain stable glucose levels between meals and overnight.

• Type 1 diabetes mellitus as part of a basal insulin regimen.
• Type 2 diabetes mellitus when basal insulin is required.
• Adjunct therapy in patients who cannot achieve glycemic control with oral agents alone.
• Use in combination with rapid‑acting insulin analogues for a basal‑bolus approach.
• Management of hyperglycemia during periods of illness or stress under physician guidance.

• Humulin Nph delivers human insulin in a neutral protamine‑hagedorn (NPH) suspension that prolongs absorption after subcutaneous injection. The insulin molecules bind to insulin receptors on muscle, adipose and hepatic cells, activating the receptor tyrosine kinase pathway. This stimulates glucose transporter (GLUT4) translocation, enhances glucose uptake, promotes glycogen synthesis, and suppresses hepatic gluconeogenesis, thereby effectively lowering systemic circulating blood glucose concentrations.

Adverse reactions to Humulin Nph may vary in frequency and severity; they are reported in clinical use and post‑marketing surveillance.

Common

• Mild hypoglycemia, often presenting as shakiness, sweating, or hunger when meals are missed or carbohydrate intake is insufficient.
• Local injection‑site reactions including redness, swelling, itching, or a transient lump at the site of administration.
• Lipodystrophy, characterized by localized accumulation or loss of subcutaneous fat after repeated injections in the same area.
• Gradual weight gain that may accompany improved glycemic control.

Serious

• Severe hypoglycemia with neuroglycopenic manifestations such as confusion, seizures, or loss of consciousness requiring immediate assistance.
• Allergic responses ranging from urticaria and angio‑edema to life‑threatening anaphylaxis.
• Edema or fluid retention causing peripheral swelling, particularly in the lower extremities.
• Rare insulin‑induced hypokalemia leading to muscle weakness, cardiac arrhythmias, or other electrolyte disturbances.

When prescribing Humulin Nph, clinicians should consider several precautionary measures to minimize risks and ensure safe use.

• Assess renal and hepatic function, as impairment may alter insulin clearance.
• Monitor blood glucose regularly to adjust dose and avoid hypoglycemia.
• Educate patients on proper injection technique and site rotation to prevent lipodystrophy.
• Review concomitant medications that can potentiate or mask hypoglycemia.
• Caution in pregnant or breastfeeding women; benefits must outweigh potential risks.
• Adjust doses during periods of illness, surgery, or changes in physical activity.

Humulin Nph can interact with other medicines, affecting glucose control or insulin action; some combinations should be avoided while others require careful monitoring.

Avoid

• Concurrent use of other long‑acting insulin products without dose adjustment.
• Combining with insulin secretagogues (e.g., sulfonylureas) at full doses, which may precipitate severe hypoglycemia.

Use with caution

• Beta‑blockers, which may mask hypoglycemia symptoms.
• Corticosteroids, which can increase insulin resistance and raise glucose levels.
• Diuretics, especially thiazides, that may affect electrolyte balance and glucose.
• Oral antidiabetic agents (e.g., metformin, DPP‑4 inhibitors) requiring dose titration.